Skip navigation
MOST POPULAR RELATED TAGS
  • TOPICS
  • SECTORS
  • COMPANIES
Pharmas Market Video Gallery
The hour's business headlines, with CNBC's Mike Huckman.
A look at the latest drug development news, with CNBC's Mike Huckman and Les Funtleyder, Miller Tabak healthcare strateg...
PHARMA WATCH LIST
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

PHARMA'S MARKET VIDEO

» More

Current DateTime: 12:08:47 06 Jul 2009
LinksList Documentid: 31171988
Expiration DateTime: 7/6/2009 12:09:08 PM

RSS FEED

» Help

Current DateTime: 12:08:48 06 Jul 2009
LinksList Documentid: 31171995
Pharma's Market Blog
Text Size
Oct.31
3:36 PM ET
Wednesday, 31 Oct 2007
Eli Lilly: Will They Get Lucky With 'One A Day' Cialis?

Eli Lilly
CNBC.com

Today's the day Eli Lilly  [LLY  Loading...      ()   ]was expected to get a Food and Drug Administration decision on the first-ever one-a-day impotence drug. Right now, the company sells Cialis for use as needed. But men could pop this one every day--like an aspirin or multi-vitamin--so the drug would always be "on board."

Yeah, I know this will lead to a whole new genre of late-night TV jokes about the nearly 10-year-old erectile dysfunction (ED) drug class. But in all seriousness, urologists (the doctors who specialize in treating ED) say there's a market for a one-a-day.

Dr. Kevin McVary at the Northwestern University School of Medicine, who does consulting and/or works on clinical trials for the ED drugmakers, says there's a "sizeable minority" of patients who would take Cialis every day. He told me that he works with couples who don't like their foreplay interrupted by what can be a mood-killing pause to take an ED drug and then sit around waiting for it to take effect. With a one-a-day version, he says, that worry is gone.

Cialis is the one that lasts 36 hours. And it takes effect faster than Pfizer's [PFE  Loading...      ()   ] Viagra and Levitra from Bayer, GlaxoSmithKline [GSK  Loading...      ()   ] and Schering-Plough [SGP  Loading...      ()   ] . Viagra and Levitra also only last a few hours or so. Sales growth of the ED drugs has slowed, but it's still around a $3-billion-a-year business. Cialis sales, for example, were up 27% in the third quarter.

But here's the rub. A Lilly spokesperson says the FDA has asked for more information on one-a-day Cialis, so a decision on approving it will likely be delayed beyond today. Deutsche Bank's Barbara Ryan is out with a research note to clients this afternoon saying the agency wants "additional analyses of existing data". So, that presumably means Lilly doesn't have to go back to square one and do more tests, it just has to crunch more numbers or something.

But you gotta love Ryan's take on all this: "Once daily dosing could appeal to men with ED who are eternal optimists or have relatively active sexual lives, and we expect it could provide some modest incremental growth to the Cialis franchise." Deutsche owns at least one percent of LLY, makes a market in the stock and has done and wants to do more investment banking for the company.

The Lilly spokesperson told me the drug is intended for men "who anticipate having sex at least twice a week." It's already approved in Europe where Lilly is launching it now. American men will just have to wait.

Questions?  Comments? 

© 2009 CNBC, Inc. All Rights Reserved

Tools:
PrintEmailAdd This share icon
Next Post


Current DateTime: 11:41:25 06 Jul 2009
LinksList Documentid: 29778428

Current DateTime: 11:26:00 06 Jul 2009
LinksList Documentid: 29779196

Current DateTime: 10:58:21 06 Jul 2009
LinksList Documentid: 29779199

Current DateTime: 01:05:26 06 Jul 2009
LinksList Documentid: 29779198
CNBCCNBC
About CNBC  |  Site Map  |  Privacy Policy  |  Terms of Service  |  Video Reprints  |  Advertise  |  Help  |  Contact
Partners: AOL Money  |  BloggingStocks.com
CNBC is a Division of NBC Universal
  Data is a real-time snapshot *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
Thomson ReutersThomson Reuters